查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1529816

結核病診斷市場規模、佔有率、趨勢分析報告：按測試類型、最終用途、地區、細分市場預測，2024-2030 年

Tuberculosis Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Nucleic Acid Testing, Detection of Latent Infection), By End-use (Diagnostic Laboratories, Hospitals), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

結核病診斷市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球結核病診斷市場規模預計將達到32.9億美元，2024年至2030年複合年成長率為5.97%。

干擾素-γ釋放測定（IGRA）、血清學技術和核酸檢測等先進診斷技術的出現導致了診斷劑的高利用率。此外，抗原檢測等照護端 (POC) 技術也提高了結核病的診斷率。

這些先進的方法，包括 POC 診斷，價格實惠、準確、方便，並且可以快速提供結果。此外，結核病負擔的增加是推動市場成長的主要因素。根據世界衛生組織（WHO）估計，2014年全球結核病患者人數約960萬人。這種高盛行率促使政府、醫療機構、研究機構和市場相關人員採取措施遏制這種感染疾病的爆發。

發展重點是提高高負擔地區的篩檢率、負擔得起的診斷、先進的調查方法、快速的臨床決策和降低死亡率。提高預防性和治療性診斷率是這些努力的最終結果。因此，診斷測試的需求迅速增加，結核病診斷市場不斷擴大。

結核病診斷市場報告亮點

  • 診斷測試在 2023 年將佔 46.92% 的佔有率，因為它們具有成本效益且易於執行。診斷實驗室測試包括塗片顯微鏡檢查和基於培養的測試。高負擔地區缺乏採用先進技術並依賴這些方法的財政和技術能力，從而促進了診斷實驗室檢測行業的成長。
  • 然而，準確度低和處理時間長是此診斷方法的限制因素。因此，醫療機構努力在發展中地區實施先進技術。
  • 因此，核酸檢測領域和潛在感染疾病檢測領域，包括皮膚檢測和IGRA，可能呈現盈利成長率。這些方法透過克服上述限制來提高診斷的負擔能力、處理時間和準確性。
  • 結核病的抗藥性是醫療專業人員關注的主要問題之一，因為錯誤的用藥方案或錯誤的劑型導致治療不當，導致結核病患者在治療過程中產生抗藥性。因此，抗藥性檢測領域也預計將呈現良好的成長動能。
  • 亞太地區人口眾多、結核病患率高，在2015年主導了全球結核病診斷市場。世界衛生組織表示，印度、中國、阿富汗和印尼等國家是控制這場疫情的優先地區。
  • 新產品發布、聯盟、併購和區域擴張是這些產業參與者採取的主要策略措施。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章結核病診斷市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 結核病診斷市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章結核病診斷市場：按測試類型進行估計和趨勢分析

  • 全球結核病診斷市場：按測試類型分類的儀表板
  • 全球結核病診斷市場：按測試類型分析差異
  • 全球結核病診斷市場：按測試類型分類的收益
  • 核酸檢測
  • 檢測潛伏感染（皮膚試驗和IGRA）
  • 抗藥性檢測（DST）
  • 噬菌體測定
  • 細胞激素檢測分析
  • 診斷測試方法
  • 放射學方法
  • 其他方法

第5章結核病診斷市場：最終用途的估計和趨勢分析

  • 全球結核病診斷市場：依最終用途分類的儀表板
  • 全球結核病診斷市場：最終用途的變化分析
  • 全球結核病診斷市場：按最終用途分類的收益
  • 診斷實驗室
  • 醫院和診所
  • 其他

第6章結核病診斷市場：按測試類型和最終用途分類的區域估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第7章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • 主要客戶
    • 2023年主要企業市場佔有率分析
    • Abbott
    • QIAGEN
    • Thermo Fisher Scientific Inc.
    • BD
    • F. Hoffmann-La Roche AG
    • Hologic, Inc.
    • Cepheid
    • DiaSorin SpA
    • Hain Lifescience GmbH
    • Oxford Immunotec
Product Code: GVR-1-68038-098-9

Tuberculosis Diagnostics Market Growth & Trends:

The global tuberculosis diagnostics market size is expected to reach USD 3.29 billion by 2030, registering a CAGR of 5.97% from 2024 to 2030, according to a new report by Grand View Research, Inc. Advent of advanced diagnostic methods such as Interferon-gamma Release Assay (IGRA), serological methods, and nucleic acid testing have resulted in the high usage rate of diagnostics. Moreover, Point of Care (POC) technologies such as antigen assays are also promoting the diagnosis rate of TB.

These advanced methods including POC diagnostics are affordable, accurate, simple, and yield quick results. Furthermore, the rising burden of TB is the primary factor responsible for the lucrative market growth. As per the World Health Organization, the global estimates of patients afflicted with TB were around 9.6 million in 2014. This high prevalence rate has led the government, healthcare organizations, research institutes, and market players to initiate endeavors directed toward containing the incidence of this infectious disease.

The increasing screening rate in the high burden regions, affordability of diagnostics, advanced methodologies, faster clinical decisions, and reduction in mortality rate are the focal areas of development. Improved preventive and curative diagnosis rates are the end results of these initiatives. This has led to a subsequent upsurge in the demand for diagnostic tests and the TB diagnostics market.

Tuberculosis Diagnostics Market Report Highlights:

  • Diagnostic laboratories dominated the test type segment with of 46.92% in 2023 as they are cost efficient and easy-to-perform. Diagnostic laboratory tests include smear microscopy and culture-based tests. The high burden regions rely on these methodologies due to their financial and technical incapability to incorporate advanced technologies thus contributing to the growth of the diagnostic laboratory tests segment.
  • However, compromised accuracy and the longer processing time are the limiting factor for the diagnostics. Hence, healthcare agencies are striving to implement advanced techniques in the developing regions.
  • As a result, nucleic acid tests segment and the latent infection detection segment, which includes skin tests and IGRA, are likely to exhibit a profitable growth rate. These methods overcome the aforementioned limitations thus improving affordability, processing time and accuracy of the diagnostic method.
  • Drug resistance in tuberculosis is one of the primary concerns for healthcare professionals as improper treatment due to wrong drug regimen and incorrect dosage forms lead to the development of drug resistance in TB patients undergoing treatment. Hence, the drug resistance detection segment is also anticipated to witness lucrative growth.
  • Asia Pacific owing to its huge population base and high burden of TB dominated the global TB diagnostics market in 2015. As per the WHO, countries such as India, China, Afghanistan, and Indonesia are priority regions for control of this communicable disease.
  • New product launches, collaboration, mergers & acquisitions, and regional expansion are the key strategic initiatives undertaken by these industry players

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Test Type
    • 1.2.2. End-use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test type and end-use outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Tuberculosis Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of TB
      • 3.2.1.2. Increasing funding program for TB diagnosis
      • 3.2.1.3. Favorable government initiatives for combating TB
      • 3.2.1.4. Surge in geriatric population
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Presence of stringent rules and regulations pertaining to diagnostics
  • 3.3. Tuberculosis Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Tuberculosis Diagnostics Market: Test Type Estimates & Trend Analysis

  • 4.1. Global Tuberculosis Diagnostics Market: Test Type Dashboard
  • 4.2. Global Tuberculosis Diagnostics Market: Test Type Movement Analysis
  • 4.3. Global Tuberculosis Diagnostics Market by Test Type, Revenue
  • 4.4. Nucleic Acid Testing
    • 4.4.1. Nucleic acid testing market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
  • 4.5. Detection of Latent Infection (Skin Test & IGRA)
    • 4.5.1. Detection of latent infection (skin test & IGRA) market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
  • 4.6. Detection of Drug Resistance (DST)
    • 4.6.1. Detection of Drug Resistance (DST) market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
  • 4.7. Phage Assay
    • 4.7.1. Phase assay market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
  • 4.8. Cytokine Detection Assay
    • 4.8.1. Cytokine detection assay market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
  • 4.9. Diagnostic Laboratory Methods
    • 4.9.1. Diagnostic laboratory methods market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
  • 4.10. Radiographic Method
    • 4.10.1. Radiographic method market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
  • 4.11. Other Methods
    • 4.11.1. Other methods market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests)

Chapter 5. Tuberculosis Diagnostics Market: End Use Estimates & Trend Analysis

  • 5.1. Global Tuberculosis Diagnostics Market: End Use Dashboard
  • 5.2. Global Tuberculosis Diagnostics Market: End Use Movement Analysis
  • 5.3. Global Tuberculosis Diagnostics Market by End-use, Revenue
  • 5.4. Diagnostic Laboratories
    • 5.4.1. Diagnostic laboratories market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
  • 5.5. Hospitals and Clinics
    • 5.5.1. Hospitals and clinics market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
  • 5.6. Others
    • 5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests)

Chapter 6. Tuberculosis Diagnostics Market: Regional Estimates & Trend Analysis by Test Type, and End-use

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. Abbott
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. QIAGEN
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Thermo Fisher Scientific Inc.
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. BD
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. F. Hoffmann-La Roche AG
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Hologic, Inc.
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Cepheid
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. DiaSorin S.p.A.
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Hain Lifescience GmbH
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Oxford Immunotec
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 4 Global Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 5 Global Nuclear Magnetic Resonance Spectroscopy, by Region, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 6 North America Nuclear Magnetic Resonance Spectroscopy, by Country, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 7 North America Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 8 North America Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 9 U.S. Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 10 U.S. Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 11 Canada Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 12 Canada Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 13 Mexico Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 14 Mexico Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 15 Europe Nuclear Magnetic Resonance Spectroscopy, by Country, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 16 Europe Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 17 Europe Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 18 Germany Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 19 Germany Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 20 UK Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 21 UK Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 22 France Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 23 France Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 24 Italy Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 25 Italy Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 26 Spain Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 27 Spain Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 28 Denmark Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 29 Denmark Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 30 Sweden Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 31 Sweden Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 32 Norway Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 33 Norway Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 34 Asia Pacific Nuclear Magnetic Resonance Spectroscopy, by Country, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 35 Asia Pacific Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 36 Asia Pacific Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 37 China Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 38 China Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 39 Japan Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 40 Japan Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 41 India Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 42 India Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 43 South Korea Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 44 South Korea Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 45 Australia Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 46 Australia Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 47 Thailand Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 48 Thailand Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 49 Latin America Nuclear Magnetic Resonance Spectroscopy, by Country, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 50 Latin America Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 51 Latin America Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 52 Brazil Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 53 Brazil Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 54 Argentina Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 55 Argentina Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 56 Middle East & Africa Nuclear Magnetic Resonance Spectroscopy, by Country, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 57 Middle East & Africa Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 58 Middle East & Africa Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 59 South Africa Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 60 South Africa Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 61 Saudi Arabia Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 62 Saudi Arabia Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 63 UAE Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 64 UAE Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 65 Kuwait Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 66 Kuwait Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Tuberculosis Diagnostics Market Segmentation
  • Fig. 8 Market Snapshot, 2023
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 14 Porter's Five Forces Analysis
  • Fig. 15 Global Tuberculosis Diagnostics Market: Test Type Movement Analysis
  • Fig. 16 Global Tuberculosis Diagnostics Market, Nucleic Acid Testing, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 17 Global Tuberculosis Diagnostics Market, Detection of Latent Infection (Skin Test & IGRA), 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 18 Global Tuberculosis Diagnostics Market, Detection of Drug Resistance (DST), 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 19 Global Tuberculosis Diagnostics Market, Phage Assay, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 20 Global Tuberculosis Diagnostics Market, Cytokine Detection Assay, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 21 Global Tuberculosis Diagnostics Market, Diagnostic Laboratory Methods, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 22 Global Tuberculosis Diagnostics Market, Radiographic Method, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 23 Global Tuberculosis Diagnostics Market, Other Methods, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 24 Global Tuberculosis Diagnostics Market: End Use Movement Analysis
  • Fig. 25 Global Tuberculosis Diagnostics Market, for Diagnostics Laboratories, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 26 Global Tuberculosis Diagnostics Market, for Hospitals and Clinics, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 27 Global Tuberculosis Diagnostics Market, for Others, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 28 Regional Marketplace: Key Takeaways
  • Fig. 29 Regional Outlook, 2023 & 2030
  • Fig. 30 Global Tuberculosis Diagnostics Market: Region Movement Analysis
  • Fig. 31 North America Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 32 U.S. Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 33 Canada Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 34 Mexico Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 35 Europe Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 36 Germany Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 37 UK Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 38 France Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 39 Italy Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 40 Spain Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 41 Denmark Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 42 Sweden Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 43 Norway Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 44 Asia Pacific Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 45 Japan Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 46 China Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 47 India Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 48 Australia Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 49 South Korea Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 50 Thailand Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 51 Latin America Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 52 Brazil Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 53 Argentina Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 54 Middle East and Africa Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 55 South Africa Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 56 Saudi Arabia Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 57 UAE Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 58 Kuwait Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)